IL-10 alters prolactin receptor activity emulating that during breast cancer

Cytokine

Volumn 51, Issue 2, 2010, Pages 144-150

  Paul, Sonali ^a   Biswas, Amlan ^b   Sasmal, Krittika ^b   Mukherjee, Subhadeep ^b   Biswas, Tapas ^b   Biswas, Ratna ^b  

^a VIVEKANANDA INSTITUTE OF MEDICAL SCIENCES   (India)

^b NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

Author keywords

Breast cancer; Interleukin 10; Peripheral blood mononuclear cells; Prolactin receptor

Indexed keywords

GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 10; MESSENGER RNA; PROLACTIN RECEPTOR; PROLACTIN RELEASING FACTOR; PROLACTIN;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER PATIENT; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; SUPERNATANT; TH1 CELL; TH2 CELL; TUMOR CELL; WESTERN BLOTTING; BLOOD; BREAST TUMOR; DIAGNOSTIC USE; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PHYSIOLOGY;

ADULT; BREAST NEOPLASMS; FEMALE; HUMANS; INTERLEUKIN-10; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; PROLACTIN; RECEPTORS, PROLACTIN; RNA, MESSENGER;

EID: 77954084470     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.04.012     Document Type: Article

References (30)

1. Yu-Lee L.Y. Prolactin modulation of immune and inflammatory responses. Recent Prog Horm Res 2002, 57:435-455.
2. + T-cell response through receptor-mediated alterations in the expression of T-bet. Immunol Cell Biol 2008, 86:616-621.
3. Sodhi A., Tripathi A. Prolactin and growth hormone induce differential cytokine and chemokine profile in murine peritoneal macrophage in vitro: involvement of p-38 MAPkinase, STAT3 and NF-kappa B. Cytokine 2008, 41:162-173.
4. Dugan A.L., Thellin O., Buckley D.J., Buckley A.R., Ogle C.K., Horseman N.D. Effects of prolactin deficiency on myelopoiesis and splenic T lymphocyte proliferation in thermally injured mice. Endocrinology 2002, 143:4147-4151.
5. Chouaib S., Asselin-Paturel C., Mami-Chouaib F., Caignard A., Blay J.Y. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 1997, 18:493-497.
6. Handel-Fernandez M.E., Cheng X., Herbert L.M., Lopez D.M. Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-gamma production in mammary tumor-bearing mice. J Immunol 1997, 158:280-286.
7. Chattopadhyay U., Biswas R. Prolactin regulates macrophage and NK cell mediated inflammation and cytotoxic response against tumor. Neuroimmune biology: growth and lactogenic hormones 2002, vol. 2:227-243. Elsevier Science B.V., Amsterdam.
8. Biswas R., Roy T., Chattopadhyay U. Prolactin induced reversal of glucocorticoid mediated apoptosis of immature cortical thymocytes is abrogated by induction of tumor. J Neuroimmunol 2006, 171:120-134.
9. Roy T., Paul S., Baral R.N., Chattopadhyay U., Biswas R. Tumor associated release of interleukin-10 alters the prolactin receptor and down-regulates prolactin responsiveness of immature cortical thymocytes. J Neuroimmunol 2007, 186:112-120.
10. Dogusan Z., Book M.L., Verdood P., Yu-Lee L.Y., Hooghe-Peters E.L. Prolactin activates interferon regulatory factor-1 expression in normal lympho-hemopoietic cells. Eur Cytokine Netw 2000, 11:435-442.
11. Chakraborty A., Chakraborty N.G., Chattopadhyay U. Prolactin response of NK cells, but not of LAK cells, is deficient in patients with carcinoma of oral cavity and during aging. Int J Cancer 1996, 66:65-69.
12. Biswas R., Chattopadhyay U. Altered prolactin response of the lymphocytes of tumor-bearing mice. Int J Cancer 1992, 50:93-98.
13. Inagaki A., Ishida T., Ishii T., Komatsu H., Iida S., Ding J., et al. Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors. Int J Cancer 2006, 118:3054-3061.
14. Smirnova O.V., Bogorad R.L. Short forms of membrane receptors: generation and role in hormonal signal transduction. Biochemistry (Mosc) 2004, 69:351-363.
15. Matera L., Contarini M., Bellone G., Forno B., Biglino A. Up-modulation of interferon-gamma mediates the enhancement of spontaneous cytotoxicity in prolactin-activated natural killer cells. Immunology 1999, 98:386-392.
16. Dogusan Z., Hooghe R., Verdood P., Hooghe-Peters E.L. Cytokine-like effects of prolactin in human mononuclear and polymorphonuclear leukocytes. J Neuroimmunol 2001, 120:58-66.
17. Yu-Lee L.Y., Luo G., Moutoussamy S., Finidori J. Prolactin and growth hormone signal transduction in lymphohaemopoietic cells. Cell Mol Life Sci 1998, 54:1067-1075.
18. Taniguchi T., Ogasawara K., Takaoka A., Tanaka N. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 2001, 19:623-655.
19. Liu J., Guan X., Tamura T., Ozato K., Ma X. Synergistic activation of interleukin-12 p35 gene transcription by interferon regulatory factor-1 and interferon consensus sequence-binding protein. J Biol Chem 2004, 279:55609-55617.
20. Daegelmann C., Herberth G., Röder S., Herbarth O., Giese T., Krämer U., et al. LISAplus study group, Association between suppressors of cytokine signalling, T-helper type 1/T-helper type 2 balance and allergic sensitization in children. Clin Exp Allergy 2007, 38:438-448.
21. Majumder B., Biswas R., Chattopadhyay U. Prolactin regulates antitumor immune response through induction of tumoricidal macrophages and release of IL-12. Int J Cancer 2002, 97:493-500.
22. Trott J.F., Hovey R.C., Koduri S., Vonderhaar B.K. Alternative splicing to exon 11 of human prolactin receptor gene results in multiple isoforms including a secreted prolactin-binding protein. J Mol Endocrinol 2003, 30:31-47.
23. Perrot-Applanat M., Gualillo O., Pezet A., Vincent V., Edery M., Kelly P.A. Dominant negative and cooperative effects of mutant forms of prolactin receptor. Mol Endocrinol 1997, 11:1020-1032.
24. Lynch K.W. Consequences of regulated pre-mRNA splicing in the immune system. Nat Rev Immunol 2004, 4:931-940.
25. Kolenko V., Wang Q., Riedy M.C., O'Shea J., Ritz J., Cathcart M.K., et al. Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas. J Immunol 1997, 159:3057-3067.
26. Pestka S., Krause C.D., Sarkar D., Walter M.R., Shi Y., Fisher P.B. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004, 22:929-979.
27. Diaz-Sanchez D., Zhang K., Nutman T.B., Saxon A. Differential regulation of alternative 3' splicing of epsilon messenger RNA variants. J Immunol 1995, 155:1930-1941.
28. Krejsgaard T., Gjerdrum L.M., Ralfkiaer E., Lauenborg B., Eriksen K.W., Mathiesen A.M., et al. Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome. Leukemia 2008, 22:2230-2239.
29. Nagata J., Kijima H., Hatanaka H., Tokunaga T., Takagi A., Mine T., et al. Correlation between interleukin 10 and vascular endothelial growth factor expression in human esophageal cancer. Int J Mol Med 2002, 10:169-172.
30. Stamm S. Signals and their transduction pathways regulating alternative splicing: a new dimension of the human genome. Hum Mol Genet 2002, 11:2409-2416.